Close
  Indian J Med Microbiol
 

Figure 3: SD-OCT images of the RE following treatment with bevacizumab; line scan showing the disappearance of the intraretinal cystoid spaces with the persistence of SFD following 1st dose of bevacizumab (a); Reduction in size of SFD following 2nd dose of bevacizumab (b); Final SD-OCT image one year after the 3rd dose of bevacizumab showing complete resolution of SFD with inner retinal hyporeflective cavity with ILM draping (c). BE: Both eyes, RE: Right eye, SD-OCT: Spectral-domain optical coherence tomography, SFD: Subfoveal detachment, OCTA: Optical coherence tomography angiography

Figure 3: SD-OCT images of the RE following treatment with bevacizumab; line scan showing the disappearance of the intraretinal cystoid spaces with the persistence of SFD following 1<sup>st</sup> dose of bevacizumab (a); Reduction in size of SFD following 2<sup>nd</sup> dose of bevacizumab (b); Final SD-OCT image one year after the 3<sup>rd</sup> dose of bevacizumab showing complete resolution of SFD with inner retinal hyporeflective cavity with ILM draping (c). BE: Both eyes, RE: Right eye, SD-OCT: Spectral-domain optical coherence tomography, SFD: Subfoveal detachment, OCTA: Optical coherence tomography angiography